Roche has reported positive results after its Phase III trial

After its Phase III trial, evaluating the casirivimab and imdevimab’s ability to reduce the risk and burden of COVID-19, Roche has reported positive results.

The trial assessed the antibodies to minimise the risk of infection among household contacts of SARS-CoV-2 infected individuals. Thus, the scientists created a cocktail containing casirivimab and imdevimab to block the infectivity of the virus.

The trial conducted with the National Institutes of Health unit National Institute of Allergy and Infectious Diseases met its primary and critical secondary endpoints.
The risk of symptomatic infections was reduced by 81% in those who weren’t infected when they entered the trial.

Furthermore, those who received the cocktail and experienced asymptomatic infection resolved their symptoms on average within seven days; this is compared to 21 days treatment with placebo.

Chief Medical Officer and Global Product Development Head of Roche, Levi Garraway, stated: “Today’s data confirm the potential dual value of casirivimab and imdevimab to reduce household COVID-19 infections and to decrease the disease burden in those who do become infected, when given as a subcutaneous option. Although vaccinations are increasing globally, there remains a critical unmet need worldwide to prevent infections and provide immediate protection from COVID-19 between close contacts.”